Fatigue is one of the most consistent and distressing symptoms reported by pediatric
oncology patients. The investigators' work has demonstrated that in the period from
diagnosis through the initial 8 weeks of treatment, adolescents and young adults with solid
tumors experience substantial fatigue that is not related to sleep disruption. Fatigue can
contribute to many adverse outcomes including poor treatment adherence, reduced social
activities, depressive symptoms, behavior problems, and poorer quality of life.
Unfortunately, no definitive intervention to reduce fatigue has been developed for pediatric
oncology patients. Investigators propose a study to estimate the feasibility and
acceptability of bright light therapy as an intervention to decrease fatigue in adolescents
and young adults who are newly diagnosed and receiving treatment for solid tumors, including
This feasibility and acceptability study will assess the rate of consent to, adherence to,
and side effects from a therapy study in a randomized trial comparing bright white light
(BWL) to dim red light (DRL). Four questionnaires will be distributed to patients and/or
their parents, depending upon the questionnaire, to study the fatigue, quality of life, mood
symptoms, and side effects of the BWL/DRL intervention in adolescents and young adults being
treated for solid tumors, including lymphoma.
- To estimate the feasibility and acceptability of a BWL intervention compared to a DRL
standard comparison group in adolescent/young adult solid tumor and lymphoma patients.
- To estimate the effect size of this intervention on measures of fatigue in order to
design a larger clinical trial of efficacy of a randomized control trial of BWL versus
DRL intervention for fatigue in pediatric oncology patients.
OTHER PRESPECIFIED OBJECTIVES:
- Estimate the effect of participant location (inpatient, hospital-based housing, or
home) on adherence.
- Estimate rates of depressive symptoms.
- Describe quality of life.
- Age 12 years or older
- Has initiated treatment as part of an active St. Jude Children's Research Hospital
(SJCRH) treatment plan
- ≤ 30 days post diagnosis of a solid tumor or lymphoma
- Patient speaks, reads and writes in English or Spanish
- Potential participant/guardian is willing to sign informed consent
- Blind or having a history of eye disease including, but not limited to, macular
degeneration, or other diagnosed retinal problems
- Undergone laser corrective eye surgery in the past 30 days
- Significant physiological or psychological impairment that interferes with
participation (e.g., migraines, bipolar disorder, psychosis, seasonal affective
- Recently started on anti-depressant medications (past one month for those on
Selective Serotonin Reuptake Inhibitors [SSRI] and past two months for those started
on Monoamine Oxidase Inhibitors [MAOI])